Ruth A. Karron spends much of her time researching Virology, Virus, Immunology, Vaccination and Respiratory Syncytial Virus Vaccines. Her Virology research is multidisciplinary, incorporating elements of Innate immune system, Recombinant virus and Microbiology. Her study looks at the relationship between Virus and topics such as Immunity, which overlap with Cytokine, Inflammation, Glycoprotein and Cellular immunity.
Her study looks at the intersection of Immunology and topics like Disease with Case-control study and Respiratory system. Her Respiratory Syncytial Virus Vaccines research integrates issues from Viral disease, Respiratory tract, Rsv vaccine and Viral shedding. Her Immunization research focuses on Live attenuated influenza vaccine and how it relates to Family medicine, Health care, Pandemic and Influenza A virus.
Ruth A. Karron focuses on Virology, Immunology, Virus, Vaccination and Immunogenicity. Her work deals with themes such as Respiratory Syncytial Virus Vaccines and Antibody, which intersect with Virology. Her work in Immunology covers topics such as Respiratory tract which are related to areas like Disease.
The concepts of her Virus study are interwoven with issues in Immunoglobulin G and Respiratory system. Her Vaccination study combines topics in areas such as Hemagglutinin, Hemagglutination assay, Pandemic and Family medicine. Ruth A. Karron works mostly in the field of Immunogenicity, limiting it down to topics relating to Rotavirus and, in certain cases, Serotype, as a part of the same area of interest.
Her main research concerns Virology, Virus, Vaccination, Respiratory Syncytial Virus Vaccines and Immunogenicity. In her study, Active immunization is strongly linked to RSV Vaccines, which falls under the umbrella field of Virology. Her work on Neutralizing antibody as part of general Virus research is often related to Virus vaccine, thus linking different fields of science.
Her work on Live attenuated influenza vaccine as part of general Vaccination study is frequently linked to Advisory committee, therefore connecting diverse disciplines of science. Her research integrates issues of Global health, Titer, Burden of disease and Rsv vaccine in her study of Respiratory Syncytial Virus Vaccines. Her Immunogenicity study combines topics from a wide range of disciplines, such as Infectivity and Antibody titer.
Ruth A. Karron mainly focuses on Virus, Virology, Virus vaccine, Public health and Clinical trial. Her Virus study incorporates themes from Respiratory Syncytial Virus Vaccines and Reactogenicity, Immunogenicity. Her research in Reactogenicity intersects with topics in Titer, Neutralizing antibody, Respiratory syncytial virus and Vaccination.
Her research related to Infectivity, Enterovirus and Rhinovirus might be considered part of Virology. Her Public health research includes elements of Infectious disease and Zika virus. Her Clinical trial research is multidisciplinary, incorporating perspectives in Respiratory tract, Respiratory system, Virus diseases and Incidence.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season.
Lisa A. Grohskopf;Leslie Z. Sokolow;Leslie Z. Sokolow;Sonja J. Olsen;Joseph S. Bresee.
Morbidity and Mortality Weekly Report (2015)
Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine
Clayton D. Harro;Yuk Ying Susana Pang;Richard B.S. Roden;Allan Hildesheim.
Journal of the National Cancer Institute (2001)
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant.
Ruth A. Karron;Deborah A. Buonagurio;Alice F. Georgiu;Stephen S. Whitehead.
Proceedings of the National Academy of Sciences of the United States of America (1997)
Prevention and Control of Seasonal Influenza with Vaccines.
Lisa A. Grohskopf;Leslie Z. Sokolow;Karen R. Broder;Sonja J. Olsen.
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control (2016)
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
Anna P. Durbin;Ruth A. Karron;Wellington Sun;David W. Vaughn.
American Journal of Tropical Medicine and Hygiene (2001)
A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease
Fernando P. Polack;Michael N. Teng;Peter L.Collins;Gregory A. Prince.
Journal of Experimental Medicine (2002)
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy
Peter F. Wright;Ruth A. Karron;Robert B. Belshe;Juliette Thompson.
The Journal of Infectious Diseases (2000)
Identification of a Recombinant Live Attenuated Respiratory Syncytial Virus Vaccine Candidate That Is Highly Attenuated in Infants
Ruth A. Karron;Peter F. Wright;Robert B. Belshe;Bhagvanji Thumar.
The Journal of Infectious Diseases (2005)
Respiratory syncytial virus and metapneumovirus
Peter L. Collins;Ruth A Karron.
Risk factors for severe respiratory syncytial virus infection among Alaska Native children
Lisa R. Bulkow;Rosalyn J. Singleton;Rosalyn J. Singleton;Ruth A. Karron;Lee H. Harrison.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: